Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus and Familial Adenomatous Polyposis (FAP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years~* A genetically confirmed APC mutation~* Classical FAP phenotype (100-1000 colorectal adenomatous polyps)~* Subtotal colectomy with ileorectal anastomosis (IRA) or total colectomy with ileo-anal pouch anastomosis (IPAA)~* Severe rectal or pouch polyposis, defined as having \>25 polyps amenable to complete removal (InSiGHT 2011 Staging System score of 3)~* Fertile patients must use effective contraception during study treatment and until 12 weeks after study treatment~Exclusion Criteria:~* Inability to give informed consent~* Participation in another interventional clinical trial~* Subjects who are pregnant or breast-feeding, proved with a negative pregnancy test if female of child-bearing potential~* Prior pelvic irradiation~* Invasive malignancy in the past 5 years~* Subjects who are HIV positive~* Subjects with severe systemic infections, current or within 2 weeks prior to study start~* Subjects with known severe restrictive or obstructive pulmonary disorders~* Known sucrase insufficiency, isomaltase insufficiency, fructose intolerance, glucose malabsorption, galactose malabsorption, galactose intolerance or Lapp-lactase deficiency~* History of pulmonary embolism or deep venous thrombosis~* Major surgery less than or equal to 2 weeks prior to enrollment or any planned surgery within treatment period~* Active post-operative complication, e.g. infection, delayed wound healing~* History of hypersensitivity to sirolimus or to drugs of similar chemical classes~* Regular NSAID use (defined as more than twice a week for 4 consecutive weeks) within 3 months prior to baseline~* Use of other FAP directed drug therapies (accepted if discontinued 3 months prior to start of the study)~* Subjects requiring systemic anticoagulation~* Co-medication that could interact with sirolimus~* Abnormal laboratory results (assessed within 14 days prior to start of study drug)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).